Kindred Biosciences (KIN) Forecast, Price Target & Analyst Ratings
NASDAQ:KIN
9.25
+0.01 (+0.11%)
At close: Aug 27, 2021
9.26
+0.01 (+0.11%)
After Hours: 8/27/2021, 8:19:13 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Kindred Biosciences (KIN).
Forecast Snapshot
Consensus Price Target
$9.69
+ 4.76% Upside
Next Earnings Forecast
Release DateMar 15, 2022
PeriodQ3 / 2021
EPS Estimate-$0.19
Revenue Estimate4.738M
ChartMill Buy Consensus
60.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.69
Upside
+ 4.76%
From current price of $9.25 to mean target of $9.69, Based on 5 analyst forecasts
Low
$9.09
Median
$9.44
High
$11.55
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
5 analysts have analysed KIN and the average price target is 9.69 null. This implies a price increase of 4.76% is expected in the next year compared to the current price of 9.25.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
60.00%
KIN was analyzed by 5 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about KIN.
In the last month the buy percentage fell by 8 points. So the trust of analysts is decreasing.
Only 5 analysts analyzed KIN. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-06-17 | Lake Street | Downgrade | Buy -> Hold |
| 2021-06-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-06-16 | Aegis Capital | Downgrade | Buy -> Hold |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 15, 2022
PeriodQ3 / 2021
EPS Estimate-$0.19
Revenue Estimate4.738M
Revenue Q2QN/A
EPS Q2Q37.28%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
KIN is expected to report earnings on 3/15/2022. The consensus EPS estimate for the next earnings is -0.19 null and the consensus revenue estimate is 4.74M null.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 117.91% | N/A 917.89% | N/A -49.68% | N/A 92.48% | N/A 13.54% | N/A 50.75% | N/A 53.01% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -1.37 | -1.10 19.71% | -1.23 -11.82% | -1.60 -30.08% | -1.58 1.25% | -0.47 70.25% | N/A -51.22% | N/A 90.05% | N/A -197.14% | N/A 54.01% | N/A |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 21 | Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.19 37.28% | -0.13 54.01% | -0.16 34.77% | -0.15 25.92% | 0.23 216.00% | -0.13 -4.55% | -0.11 29.03% | -0.09 38.65% | -0.07 -131.35% | -0.05 62.49% |
| Revenue Q2Q % growth | 4.738M | 7.59M | 5.763M 64.36% | 6.443M 17.55% | 30.33M 540.15% | 7.39M -2.64% | 11.368M 97.25% | 12.789M 98.48% | 14.21M -53.15% | 15.631M 111.52% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
15.80%
EPS Next 5 Year
12.40%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
3.21%
Revenue Next 5 Year
20.46%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Kindred Biosciences / KIN Forecast FAQ
What do analysts expect the price target to be for Kindred Biosciences (KIN)?
5 analysts have analysed KIN and the average price target is 9.69 null. This implies a price increase of 4.76% is expected in the next year compared to the current price of 9.25.
Can you provide the upcoming earnings date for Kindred Biosciences?
Kindred Biosciences (KIN) will report earnings on 2022-03-15, after the market close.
What are the consensus estimates for KIN stock next earnings?
The consensus EPS estimate for the next earnings of Kindred Biosciences (KIN) is -0.19 null and the consensus revenue estimate is 4.74M null.
How do analysts rate Kindred Biosciences (KIN)?
The consensus rating for Kindred Biosciences (KIN) is 60 / 100 . This indicates that analysts generally have a neutral outlook on the stock.